Journal of Clinical Endocrinology & Metabolism, Vol 79, 441-446, Copyright © 1994 by Endocrine Society

ARTICLES

Impaired cardiac performance is a distinct feature of uncomplicated acromegaly

S Fazio, A Cittadini, A Cuocolo, B Merola, D Sabatini, A Colao, B Biondi, G Lombardi and L Sacca
Department of Internal Medicine, Federico II University Medical School, Naples, Italy.

This study was designed to assess right and left ventricular function in patients with active acromegaly. To this end, 26 acromegalic patients (9 of whom had arterial hypertension) and 15 normal subjects of comparable age and sex distribution were studied by radionuclide angiography at rest and during supine bicycle-ergometer exercise and echocardiography. At rest, the filling rates of left (-19%; P < 0.005) and right ventricle (-32%; P < 0.001) were significantly reduced in acromegalic patients, whereas right and left ventricle ejection fractions (EFs) were normal. During physical exercise, EF was considerably lower in the acromegalic patients than in controls. This was true for both left (61 +/- 11% vs. 75 +/- 8%; P < 0.001) and right ventricle (45 +/- 13 vs. 58 +/- 11%; P < 0.002). In as many as 73% of patients, EF increased less than 5%, thus fulfilling the criteria for impaired cardiac performance. Left ventricular mass index was 60% greater in acromegalics than in controls (P < 0.001). A significant difference in left ventricular mass index was also present when normotensive acromegalic patients were compared with controls (P < 0.001). No significant difference in the indices of systolic and diastolic function was observed between the subgroups of normotensive and hypertensive acromegalics, either at rest or during exercise. The data demonstrate that in uncomplicated acromegaly, besides cardiac hypertrophy, there are also important alterations of systolic and diastolic function of both ventricles, leading to a significant impairment of cardiac performance.

This article has been cited by other articles:

				H. Gouya, O. Vignaux, P. Le Roux, P. Chanson, J. Bertherat, X. Bertagna, and P. Legmann Rapidly Reversible Myocardial Edema in Patients with Acromegaly: Assessment with Ultrafast T2 Mapping in a Single-Breath-Hold MRI Sequence Am. J. Roentgenol., June 1, 2008; 190(6): 1576 - 1582. [Abstract] [Full Text] [PDF]

				F. Bogazzi, L. Battolla, C. Spinelli, G. Rossi, S. Gavioli, V. Di Bello, C. Cosci, C. Sardella, D. Volterrani, E. Talini, et al. Risk Factors for Development of Coronary Heart Disease in Patients with Acromegaly: A Five-Year Prospective Study J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4271 - 4277. [Abstract] [Full Text] [PDF]

				F. Bogazzi, F. Raggi, F. Ultimieri, D. Russo, A. Manariti, A. D'Alessio, P. Viacava, G. Fanelli, M. Gasperi, L. Bartalena, et al. Cardiac expression of adenine nucleotide translocase-1 in transgenic mice overexpressing bovine GH J. Endocrinol., September 1, 2007; 194(3): 521 - 527. [Abstract] [Full Text] [PDF]

				L. J. Woodhouse, A. Mukherjee, S. M. Shalet, and S. Ezzat The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults Endocr. Rev., May 1, 2006; 27(3): 287 - 317. [Abstract] [Full Text] [PDF]

				S. Bhayana, G. L. Booth, S. L. Asa, K. Kovacs, and S. Ezzat The Implication of Somatotroph Adenoma Phenotype to Somatostatin Analog Responsiveness in Acromegaly J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6290 - 6295. [Abstract] [Full Text] [PDF]

				A. Colao, D. Ferone, P. Marzullo, and G. Lombardi Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management Endocr. Rev., February 1, 2004; 25(1): 102 - 152. [Abstract] [Full Text] [PDF]

				L. Spinelli, M. Petretta, G. Verderame, G. Carbone, A. A. Venetucci, A. Petretta, W. Acampa, D. Bonaduce, A. Colao, and A. Cuocolo Left Ventricular Diastolic Function and Cardiac Performance during Exercise in Patients with Acromegaly J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4105 - 4109. [Abstract] [Full Text] [PDF]

				R. N. Clayton Cardiovascular Function in Acromegaly Endocr. Rev., June 1, 2003; 24(3): 272 - 277. [Abstract] [Full Text] [PDF]

				J. W. A. Smit, Y. J. H. Janssen, H. J. Lamb, E. E. van der Wall, M. P. M. Stokkel, E. Viergever, N. R. Biermasz, J. J. Bax, H. W. Vliegen, A. de Roos, et al. Six Months of Recombinant Human GH Therapy in Patients with Ischemic Cardiac Failure Does Not Influence Left Ventricular Function and Mass J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4638 - 4643. [Abstract] [Full Text] [PDF]

				G.Y.H Lip, D.C Felmeden, F.L Li-Saw-Hee, and D.G Beevers Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? Eur. Heart J., October 2, 2000; 21(20): 1653 - 1665. [PDF]

				E. Bollano, E. Omerovic, M. Bohlooly-Y, V. Kujacic, B. Madhu, J. Tornell, O. Isaksson, B. Soussi, W. Schulze, M. L. X. Fu, et al. Impairment of Cardiac Function and Bioenergetics in Adult Transgenic Mice Overexpressing the Bovine Growth Hormone Gene Endocrinology, June 1, 2000; 141(6): 2229 - 2235. [Abstract] [Full Text] [PDF]

				S. Fazio, A. Cittadini, B. Biondi, E. A. Palmieri, G. Riccio, F. Bonè, U. Oliviero, and L. Saccà Cardiovascular Effects of Short-Term Growth Hormone Hypersecretion J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 179 - 182. [Abstract] [Full Text]

				M. C. DELAUGHTER, G. E. TAFFET, M. L. FIOROTTO, M. L. ENTMAN, and R. J. SCHWARTZ Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice FASEB J, November 1, 1999; 13(14): 1923 - 1929. [Abstract] [Full Text]

				A. Colao, A. Cuocolo, P. Marzullo, E. Nicolai, D. Ferone, A. M. D. Morte, M. Petretta, M. Salvatore, and G. Lombardi Impact of Patient's Age and Disease Duration on Cardiac Performance in Acromegaly: A Radionuclide Angiography Study J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1518 - 1523. [Abstract] [Full Text]

				A. Frustaci, C. Chimenti, M. Setoguchi, S. Guerra, S. Corsello, F. Crea, A. Leri, J. Kajstura, P. Anversa, and A. Maseri Cell Death in Acromegalic Cardiomyopathy Circulation, March 23, 1999; 99(11): 1426 - 1434. [Abstract] [Full Text] [PDF]

				A. Colao, A. Cuocolo, P. Marzullo, E. Nicolai, D. Ferone, L. Florimonte, M. Salvatore, and G. Lombardi Effects of 1-Year Treatment with Octreotide on Cardiac Performance in Patients with Acromegaly J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 17 - 23. [Abstract] [Full Text]

				L. Sacca Growth hormone: a newcomer in cardiovascular medicine Cardiovasc Res, October 1, 1997; 36(1): 3 - 9. [Full Text] [PDF]

				R. Lopez-Velasco, H. F. Escobar-Morreale, B. Vega, E. Villa, J. M. Sancho, J. L. Moya-Mur, and R. Garcia-Robles Cardiac Involvement in Acromegaly: Specific Myocardiopathy or Consequence of Systemic Hypertension? J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1047 - 1053. [Abstract] [Full Text] [PDF]

				A. Cittadini, H. Stromer, S. E. Katz, R. Clark, A. C. Moses, J. P. Morgan, and P. S. Douglas Differential Cardiac Effects of Growth Hormone and Insulin-like Growth Factor1 in the Rat : A Combined In Vivo and In Vitro Evaluation Circulation, February 15, 1996; 93(4): 800 - 809. [Abstract] [Full Text]